Core Investor of Core Scientific Plans to Vote Against Inadequate $9B Acquisition Proposed by CoreWeave
In a surprising turn of events, Two Seas Capital, the largest active shareholder of Core Scientific, has voiced its opposition to the proposed $9 billion all-stock sale of Core Scientific to CoreWeave. The investment firm believes the transaction materially undervalues Core Scientific and exposes shareholders to substantial economic risk.
Two Seas Capital argues that the deal unfairly favors CoreWeave at the expense of Core Scientific shareholders by not properly reflecting Core Scientific’s strategic value in high-performance computing and AI infrastructure. The deal's all-stock structure, without price collars or cash components, leaves Core Scientific shareholders vulnerable to CoreWeave’s stock volatility.
In an open letter, Two Seas Capital outlined its concerns and announced its intention to vote against the transaction unless terms are revised to better represent Core Scientific’s long-term value. This opposition could signal a potential proxy battle aimed at protecting shareholder interests.
The perceived undervaluation of Core Scientific, excessive exposure to stock price volatility, and the deal structure favoring CoreWeave are the key reasons for Two Seas Capital's opposition. The risk of substantial economic downside for Core Scientific shareholders is another significant concern.
The opposition from Two Seas Capital has contributed to a drop in Core Scientific's stock price by over 8% following the public opposition announcement. Meanwhile, the stock of CoreWeave has fallen by between 26% and 30% since the deal was announced, reducing the effective valuation.
Jeffrey Emanuel, founder and CEO of Pastel Network, states that investors against a stock transaction often want more cash or a less volatile security. He points out that investors who began as distressed debt investors tend to be more activist and aggressive in defending their rights.
The wildly inflated valuation of CoreWeave stock is at issue, particularly with its IPO lockup set to expire in a month. Two Seas Capital considers the proposed sale to be "inadequate" and unfavorable to existing shareholders.
The deal pegs each Core Scientific share to 0.1235 of a CoreWeave share. A shareholder vote on the deal is expected later this year, adding potential volatility to both companies' shares. Core Scientific's shares showed a modest recovery in intraday trading on Thursday, rising 1.7% to $14.35.
The IPO lockup expiry of CoreWeave is expected to put pressure on the CoreWeave share price, according to Emanuel. Some investors are scrutinizing the deal’s terms, citing patterns in other contested all-stock mergers.
In conclusion, the opposition from Two Seas Capital highlights the concerns of many investors regarding the proposed sale of Core Scientific to CoreWeave. The deal's structure, perceived undervaluation, and potential exposure to stock price volatility are key issues that need to be addressed to gain the approval of Core Scientific's shareholders.
- Two Seas Capital argues that the all-stock sale of Core Scientific to CoreWeave unfairly favors CoreWeave at the expense of Core Scientific shareholders.
- The opposition from Two Seas Capital could signal a potential proxy battle aimed at protecting shareholder interests.
- Jeffrey Emanuel, founder and CEO of Pastel Network, states that investors against a stock transaction often want more cash or a less volatile security.
- The IPO lockup expiry of CoreWeave is expected to put pressure on the CoreWeave share price, according to Emanuel.
- In conclusion, the concerns of many investors regarding the proposed sale of Core Scientific to CoreWeave focus on the deal's structure, perceived undervaluation, and potential exposure to stock price volatility.
